Terms: = Bone cancer AND SETBP1, Q9UEF3, Q6P6C3, A6H8W5, Q9Y6X0, 26040, SEB, KIAA0437, ENSG00000152217
33 results:
1. First-hit setbp1 mutations cause a myeloproliferative disorder with bone marrow fibrosis.
Crespiatico I; Zaghi M; Mastini C; D'Aliberti D; Mauri M; Mercado CM; Fontana D; Spinelli S; Crippa V; Inzoli E; Manghisi B; Civettini I; Ramazzotti D; Sangiorgio V; Gengotti M; Brambilla V; Aroldi A; Banfi F; Barone C; Orsenigo R; Riera L; Riminucci M; Corsi A; Breccia M; Morotti A; Cilloni D; Roccaro A; Sacco A; Stagno F; Serafini M; Mottadelli F; Cazzaniga G; Pagni F; Chiarle R; Azzoni E; Sessa A; Gambacorti-Passerini C; Elli EM; Mologni L; Piazza R
Blood; 2024 Apr; 143(14):1399-1413. PubMed ID: 38194688
[TBL] [Abstract] [Full Text] [Related]
2. U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity.
Badar T; Vanegas YAM; Nanaa A; Foran JM; Al-Kali A; Mangaonkar A; Murthy H; Alkhateeb HB; Viswanatha D; He R; Shah M; Yi CA; Litzow MR; Gangat N; Tefferi A; Patnaik MM
Blood Cancer J; 2023 Sep; 13(1):149. PubMed ID: 37735430
[TBL] [Abstract] [Full Text] [Related]
3. Haploidentical donor hematopoietic cell transplantation for myelodysplastic/myeloproliferative overlap neoplasms: results from a North American collaboration.
Jain T; Tsai HL; Elmariah H; Vachhani P; Karantanos T; Wall SA; Gondek LP; Bashey A; Keyzner A; Tamari R; Grunwald MR; Abedin S; Nadiminti KV; Iqbal M; Gerds AT; Viswabandya A; McCurdy SR; Al Malki MM; Varadhan R; Ali H; Gupta V; Jones RJ; Otoukesh S
Haematologica; 2023 Dec; 108(12):3321-3332. PubMed ID: 37408464
[TBL] [Abstract] [Full Text] [Related]
4. Co-occurring mutations in ASXL1, SRSF2, and setbp1 define a subset of myelodysplastic/ myeloproliferative neoplasm with neutrophilia.
Jain T; Ware AD; Dalton WB; Pasca S; Tsai HL; Gocke CD; Gondek LP; Xian RR; Borowitz MJ; Levis MJ
Leuk Res; 2023 Aug; 131():107345. PubMed ID: 37354804
[TBL] [Abstract] [Full Text] [Related]
5. Somatic genetic alterations predict hematological progression in GATA2 deficiency.
Largeaud L; Collin M; Monselet N; Vergez F; Fregona V; Larcher L; Hirsch P; Duployez N; Bidet A; Luquet I; Bustamante J; Dufrechou S; Prade N; Nolla M; Hamelle C; Tavitian S; Habib C; Meynier M; Bellanne-Chantelot C; Donadieu J; De Fontbrune FS; Fieschi C; Ferster A; Delhommeau F; Delabesse E; Pasquet M
Haematologica; 2023 Jun; 108(6):1515-1529. PubMed ID: 36727400
[TBL] [Abstract] [Full Text] [Related]
6. Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management.
Patnaik MM; Tefferi A
Am J Hematol; 2023 Apr; 98(4):681-689. PubMed ID: 36601682
[TBL] [Abstract] [Full Text] [Related]
7. Clinical and Molecular Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria.
Gurnari C; Pagliuca S; Prata PH; Galimard JE; Catto LFB; Larcher L; Sebert M; Allain V; Patel BJ; Durmaz A; Pinto AL; Inacio MCB; Hernandez L; Dhedin N; Caillat-Zucman S; Clappier E; Sicre de Fontbrune F; Voso MT; Visconte V; Peffault de Latour R; Soulier J; Calado RT; Socié G; Maciejewski JP
J Clin Oncol; 2023 Jan; 41(1):132-142. PubMed ID: 36054881
[TBL] [Abstract] [Full Text] [Related]
8. Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy.
Karantanos T; Tsai HL; Gondek LP; DeZern AE; Ghiaur G; Dalton WB; Gojo I; Prince GT; Webster J; Ambinder A; Smith BD; Levis MJ; Varadhan R; Jones RJ; Jain T
Leuk Lymphoma; 2022 Aug; 63(8):1942-1948. PubMed ID: 35379077
[TBL] [Abstract] [Full Text] [Related]
9. Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the bone Marrow Pathology Group.
Kanagal-Shamanna R; Orazi A; Hasserjian RP; Arber DA; Reichard K; Hsi ED; Bagg A; Rogers HJ; Geyer J; Darbaniyan F; Do KA; Devins KM; Pozdnyakova O; George TI; Cin PD; Greipp PT; Routbort MJ; Patel K; Garcia-Manero G; Verstovsek S; Medeiros LJ; Wang SA; Bueso-Ramos C
Mod Pathol; 2022 Apr; 35(4):470-479. PubMed ID: 34775472
[TBL] [Abstract] [Full Text] [Related]
10. Gender-related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
Karantanos T; Gondek LP; Varadhan R; Moliterno AR; DeZern AE; Jones RJ; Jain T
Br J Haematol; 2021 Jun; 193(6):1142-1150. PubMed ID: 34028801
[TBL] [Abstract] [Full Text] [Related]
11. Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia.
Montalban-Bravo G; Kanagal-Shamanna R; Sasaki K; Masarova L; Naqvi K; Jabbour E; DiNardo CD; Takahashi K; Konopleva M; Pemmaraju N; Kadia TM; Ravandi F; Daver N; Borthakur G; Estrov Z; Khoury JD; Loghavi S; Soltysiak KA; Pierce S; Bueso-Ramos C; Patel KP; Verstovsek S; Kantarjian HM; Bose P; Garcia-Manero G
Cancer; 2021 Sep; 127(17):3113-3124. PubMed ID: 33914911
[TBL] [Abstract] [Full Text] [Related]
12. Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms.
Palomo L; Meggendorfer M; Hutter S; Twardziok S; Ademà V; Fuhrmann I; Fuster-Tormo F; Xicoy B; Zamora L; Acha P; Kerr CM; Kern W; Maciejewski JP; Solé F; Haferlach C; Haferlach T
Blood; 2020 Oct; 136(16):1851-1862. PubMed ID: 32573691
[TBL] [Abstract] [Full Text] [Related]
13. Decoding bone Marrow Fibrosis in Myelodysplastic Syndromes.
Melody M; Al Ali N; Zhang L; Ramadan H; Padron E; Sallman D; Sweet K; Lancet J; List A; Bennett JM; Komrokji R
Clin Lymphoma Myeloma Leuk; 2020 May; 20(5):324-328. PubMed ID: 32044274
[TBL] [Abstract] [Full Text] [Related]
14. Targeted sequencing aids in identifying clonality in chronic myelomonocytic leukemia.
Hwang SM; Kim SM; Nam Y; Kim J; Kim S; Ahn YO; Park Y; Yoon SS; Shin S; Kwon S; Lee DS
Leuk Res; 2019 Sep; 84():106190. PubMed ID: 31377458
[TBL] [Abstract] [Full Text] [Related]
15. Comprehensive mutation profiling and mRNA expression analysis in atypical chronic myeloid leukemia in comparison with chronic myelomonocytic leukemia.
Faisal M; Stark H; Büsche G; Schlue J; Teiken K; Kreipe HH; Lehmann U; Bartels S
Cancer Med; 2019 Feb; 8(2):742-750. PubMed ID: 30635983
[TBL] [Abstract] [Full Text] [Related]
16. Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: "2019 Update on Diagnosis, Risk-stratification, and Management".
Patnaik MM; Tefferi A
Am J Hematol; 2019 Apr; 94(4):475-488. PubMed ID: 30618061
[TBL] [Abstract] [Full Text] [Related]
17. bone marrow - mesenchymal stem cells impact on the U937 cells in the presence of staphylococcal enterotoxin B (seb).
Ejtehadifar M; Halabian R; Ghazavi A; Khansarinejad B; Mosayebi G; Imani Fooladi AA
Clin Exp Pharmacol Physiol; 2018 Aug; 45(8):849-858. PubMed ID: 29655181
[TBL] [Abstract] [Full Text] [Related]
18. Coexisting of bone marrow fibrosis, dysplasia and an X chromosomal abnormality in chronic neutrophilic leukemia with CSF3R mutation: a case report and literature review.
Wu XB; Wu WW; Zhou Y; Wang X; Li J; Yu Y
BMC Cancer; 2018 Mar; 18(1):343. PubMed ID: 29587671
[TBL] [Abstract] [Full Text] [Related]
19. Chronic neutrophilic leukemia: 2018 update on diagnosis, molecular genetics and management.
Elliott MA; Tefferi A
Am J Hematol; 2018 Aug; 93(4):578-587. PubMed ID: 29512199
[TBL] [Abstract] [Full Text] [Related]
20. Anti-cancer effects of Staphylococcal Enterotoxin type B on U266 cells co-cultured with Mesenchymal Stem Cells.
Ejtehadifar M; Halabian R; Fooladi AAI; Ghazavi A; Mosayebi G
Microb Pathog; 2017 Dec; 113():438-444. PubMed ID: 29170042
[TBL] [Abstract] [Full Text] [Related]
[Next]
